Prime Medicine, Inc.
PRME
$3.49
$0.195.89%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 3.69% | 4.95% | -13.39% | 35.60% | -3.57% |
| Total Depreciation and Amortization | 20.73% | 21.20% | 29.28% | 37.69% | 26.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 63.74% | -32.80% | 31.18% | 30.61% | 0.82% |
| Change in Net Operating Assets | -96.43% | 111.54% | 74.58% | 238.13% | 611.80% |
| Cash from Operations | -35.22% | 8.97% | 27.84% | 137.03% | 33.84% |
| Capital Expenditure | 80.66% | 17.35% | -4.22% | 2.66% | 56.10% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -277.99% | -50.63% | -30.58% | 16.04% | 248.07% |
| Cash from Investing | -282.99% | -59.81% | -28.92% | 16.88% | 233.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 260.28% | 462.86% | -- | -99.48% | 12,011.01% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -75.81% | -- | -- |
| Cash from Financing | 275.85% | 462.86% | -96.19% | -99.48% | 12,011.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -72.05% | 0.31% | -272.28% | 2,804.36% | 182.15% |